Saturday, May 13, 2023 12:30 PM – 1:15 PM ET Exhibit Hall D, Room 2
Exhibitor Workshop: BioLegend
Stimulation with a Superagonistic Anti-CD28 Antibody Shows Treg Expansion and Provides an In Vitro Model for Immunotherapeutic Research
- Rebecca Nickle, Ph.D., Applications Scientist
From bench to bedside, development of immunotherapeutic treatments requires the use of sophisticated technologies and applications to comprehensively describe and understand immunological processes. Here, using BioLegend’s cutting edge tools, we characterized the cellular and molecular changes that occur upon human T cell stimulation with a novel anti-CD28 superagonistic monoclonal antibody. Our workflow includes cell isolation using our magnetic separation MojoSort™ Human CD3+ T cell isolation kit, followed by activation using the Ultra-LEAF™ CD28 superagonistic monoclonal antibody, and expansion using our recombinant proteins. Resulting cultures are then subject to T cell subset characterization using LEGENDplex™ multiplex soluble analyte analysis, intracellular and surface protein analysis with our pre-defined multicolor cytometry panels, and integrated multiomic single -cell protein and RNA analysis with our TotalSeq™-A Human Universal Cocktail. Our data reveals the cellular and molecular signature of a potent human Treg activation and expansion promoted by our unique CD28 superagonistic monoclonal antibody. Taken together, we show how a full suite of BioLegend’s reagents and applications facilitate immunotherapeutic research to advance our understanding of complex immunological processes.